Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your melanoma must have spread to other parts of the body and is not curable with surgery.
- You need to be able to do your daily activities with little or no help (ECOG score 0 or 1).
- You must not have had prior treatment with the study drugs cemiplimab or ziv-aflibercept.
- You cannot have active or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery helps treat melanoma that has spread to nearby lymph nodes or a small number of other sites. The goal is to shrink tumors and improve surgical outcomes.
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
This trial tests a new combination of drugs (iparomlimab, tuvoraleimab, bevacizumab, and chemotherapy) as a first or second treatment for advanced acral or mucosal melanoma. It aims to see if this mix can help shrink or control the cancer.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.